Brenda Medina

Brenda Medina is a dynamic, innovative leader in the Pharmaceutical industry.  She has upwards of 20 years of clinical business and technology operations experience. 

Currently Brenda is the VP, Tech Delivery and Vendor Operations at Mediata :Dassault Systemes where her main responsibility includes the oversight and alignment of the R&D strategic pillars to the execution , integration and operations of the 3DS India teams assigned to R&D.   She has been at Medidata since September 2020. 

Most recently Brenda was the Sr. Director of Development Business Operations at Nektar Therapeutics, Inc.  She led a team, strategy, and execution for the Site Contract Negotiations and the Vendor Outsourcing Department. 

Before Nektar, Brenda was the Director, Development Science Business Operations for BioMarin Pharmaceuticals.  She led a team, strategy, and execution of Site Budget Feasibility, Creation, Negotiation, Payments, Outsourcing, Contracts, Vendor Management, and Reporting Department. 

While at BioMarin, she also established the Analytics Department and Portfolio Planning for Financial Management of clinical trials function. Just like at Eisai, she led the development, implementations of an Analytics Platform that integrated operations and financial data.  Including all the clinical system integrations.  

Before BioMarin, she was the Global Head & Director of the Clinical Business Operations Department. She was responsible for the functions of Study Budget Management, R&D Aggregate Spend tracking& Reporting, Fair Market Value Benchmarking, Strategic Meeting Management, Clinical Insurance, and Clinical System Implementation and Analysis of all the mentioned functions.  Brenda has created numerous projects that have taken a data-driven model to identify and produce drivers for Business decisions. She was a critical member of Eisai’s Innovation team.  

 She is a clinical business and technology expert. She has developed the process and tools for the study budget management process, site feasibility, and oversight, including Investigator Benchmarking, FMV, Budget Negotiations, Reconciliation, and Aggregate Spend Reporting.   

In al of her roles, Brenda has been the lead to some significant projects that commenced with data analytics, utilize financial metrics to the improvement of the overall Operational Clinical Development life cycle.  

Before Eisai, Brenda has the right balance mix of experience in Clinical Arena from Biotech and the Finance Arena from several auditing and private firms.  

Brenda’s earned her degree in Accounting and Computer Information Systems from Dowling College. Through her experience and education, she has been able to become a well-established Translator of the Clinical Development process.   She is well equipped to direct and inform Finance, and IT teams on requirements and process improvements and a Financial and Technology Liaison to the Clinical Teams, a role and department (Business Operations) she has established at Eisai, BioMarin, and now at Nektar.   

In her spare time, Brenda enjoys professional Latin dancing with her partner and spending time with her 9-year-old twins Yandel & SilBre.